<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Standards and Guidelines | Tissuepathology.com</title>
	<atom:link href="https://tissuepathology.com/category/posts/standards-and-guidelines/feed/" rel="self" type="application/rss+xml" />
	<link>https://tissuepathology.com</link>
	<description>Educational and informative</description>
	<lastBuildDate>Thu, 04 Dec 2025 13:51:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://tissuepathology.com/wp-content/uploads/2017/07/cropped-Portrait_640x960px-32x32.png</url>
	<title>Standards and Guidelines | Tissuepathology.com</title>
	<link>https://tissuepathology.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Proscia Achieves SOC 2 Type II Certification, Strengthening Enterprise Trust</title>
		<link>https://tissuepathology.com/2025/12/04/proscia-achieves-soc-2-type-ii-certification-strengthening-enterprise-trust/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Thu, 04 Dec 2025 13:51:20 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Data Management]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[General Healthcare News]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Laboratory Compliance]]></category>
		<category><![CDATA[Laboratory Information Systems]]></category>
		<category><![CDATA[Laboratory Management & Operations]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[availability]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[confidentiality]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[merican Institute of Certified Public Accountants]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Proscia]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[SOC 2 Type II Certification]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=24093</guid>

					<description><![CDATA[<p>Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale PHILADELPHIA – December 3, 2025 – Proscia®, a pathology AI company, has successfully completed its SOC 2 Type II audit. This milestone underscores the company’s enterprise-grade security and operational rigor, reinforcing its role as the partner of choice for large-scale digital pathology [&#8230;]</p>
The post <a href="https://tissuepathology.com/2025/12/04/proscia-achieves-soc-2-type-ii-certification-strengthening-enterprise-trust/">Proscia Achieves SOC 2 Type II Certification, Strengthening Enterprise Trust</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology</title>
		<link>https://tissuepathology.com/2025/07/25/philips-advances-minimally-invasive-therapy-procedures-in-prostate-cancer-care-with-fda-510k-clearance-for-image-guided-navigation-technology/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Fri, 25 Jul 2025 12:19:42 +0000</pubDate>
				<category><![CDATA[Anatomic Pathology]]></category>
		<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[General Healthcare News]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[FDA 501(k) clearance]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[image-guided navigation]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Philips]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=23803</guid>

					<description><![CDATA[<p>Philips: Supporting prostate cancer diagnosis with more precise guidance for clinicians, offering better patient care  Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with the FDA 510(k) clearance of the latest Philips UroNav version. The system includes a [&#8230;]</p>
The post <a href="https://tissuepathology.com/2025/07/25/philips-advances-minimally-invasive-therapy-procedures-in-prostate-cancer-care-with-fda-510k-clearance-for-image-guided-navigation-technology/">Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Indica Labs: Pharma Services Launches GCP-Compliant Image Analysis Service</title>
		<link>https://tissuepathology.com/2025/07/09/indica-labs-pharma-services-launches-gcp-compliant-image-analysis-service/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Wed, 09 Jul 2025 11:48:58 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Laboratory Compliance]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[Good Clinical Practice]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Indica Labs]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Pharma Services]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=23764</guid>

					<description><![CDATA[<p>Albuquerque, NM, July 8, 2025 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces that their Pharma Services team is offering quantitative image analysis studies designed and performed to Good Clinical Practice (GCP) standards. With GCP image analysis services, customers can rest assured that the quantitative image analysis data in their translational and [&#8230;]</p>
The post <a href="https://tissuepathology.com/2025/07/09/indica-labs-pharma-services-launches-gcp-compliant-image-analysis-service/">Indica Labs: Pharma Services Launches GCP-Compliant Image Analysis Service</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Navigating the IVDR: How Aiosyn prioritized compliance from day one</title>
		<link>https://tissuepathology.com/2025/05/28/navigating-the-ivdr-how-aiosyn-prioritized-compliance-from-day-one/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Wed, 28 May 2025 11:22:02 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Blogs]]></category>
		<category><![CDATA[Clinical Pathology]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Aiosyn]]></category>
		<category><![CDATA[Blog]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[IVDD]]></category>
		<category><![CDATA[IVDR]]></category>
		<category><![CDATA[mitotic figure counting]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[post-market surveillance]]></category>
		<category><![CDATA[regulations]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=23679</guid>

					<description><![CDATA[<p>From the Aiosyn Blog IVDR represents a significant overhaul of regulations requiring more rigorous oversight, clinical validation assessed by a Notified Body, and stricter post-market surveillance (PMS). Aiosyn’s AI-powered solution for mitotic figure counting was built from the ground up to comply with IVDR’s highest regulatory standards rather than transitioning from the superseded IVDD. Aiosyn [&#8230;]</p>
The post <a href="https://tissuepathology.com/2025/05/28/navigating-the-ivdr-how-aiosyn-prioritized-compliance-from-day-one/">Navigating the IVDR: How Aiosyn prioritized compliance from day one</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Aiforia secures IVDR certification, paving the way for expanded clinical portfolio in Europe</title>
		<link>https://tissuepathology.com/2025/02/20/aiforia-secures-ivdr-certification-paving-the-way-for-expanded-clinical-portfolio-in-europe/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Thu, 20 Feb 2025 13:57:52 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Clinical Laboratories]]></category>
		<category><![CDATA[Clinical Pathology]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Image Analysis]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Press Release]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[Whole slide]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Aiforia]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[BSI Group]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[IVDR certification]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[prostate cancer]]></category>
		<category><![CDATA[Software]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=23431</guid>

					<description><![CDATA[<p>Aiforia obtained the In Vitro Diagnostic Regulation (IVDR) certification and successfully launches three new CE-IVD marked AI solutions for breast and prostate cancer diagnostics Aiforia Technologies Plc, Press Release, February 20, 2025 at 10:30 a.m. EET Aiforia Technologies Plc, a provider of cutting-edge AI-assisted medical software solutions, announced today that it has successfully obtained the [&#8230;]</p>
The post <a href="https://tissuepathology.com/2025/02/20/aiforia-secures-ivdr-certification-paving-the-way-for-expanded-clinical-portfolio-in-europe/">Aiforia secures IVDR certification, paving the way for expanded clinical portfolio in Europe</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CAP releases updated guideline for validation of IHC assays</title>
		<link>https://tissuepathology.com/2024/02/28/cap-releases-updated-guideline-for-validation-of-ihc-assays/</link>
		
		<dc:creator><![CDATA[Erica Goodpaster]]></dc:creator>
		<pubDate>Wed, 28 Feb 2024 13:03:25 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Digital Pathology News]]></category>
		<category><![CDATA[Pathology News]]></category>
		<category><![CDATA[Standards and Guidelines]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[CAP]]></category>
		<category><![CDATA[College of American Pathologists]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[IHC assays]]></category>
		<category><![CDATA[image analysis]]></category>
		<category><![CDATA[Pathology]]></category>
		<category><![CDATA[Validation]]></category>
		<guid isPermaLink="false">https://tissuepathology.com/?p=22669</guid>

					<description><![CDATA[<p>The College of American Pathologists (CAP) has updated its evidence-based guideline for analytic validation of immunohistochemical (IHC) assays to provide increased accuracy and consistency in laboratory practices. Many of the recommendations published in the original 2014 guideline have remained the same. However, there are new recommendations and modifications in the update developed through assessing evidence [&#8230;]</p>
The post <a href="https://tissuepathology.com/2024/02/28/cap-releases-updated-guideline-for-validation-of-ihc-assays/">CAP releases updated guideline for validation of IHC assays</a> first appeared on <a href="https://tissuepathology.com">Tissuepathology.com</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
